Geneva, Switzerland, October 2018. Following the recent successful financing of GBC-R1, a new molecule to treat allergic diseases (see also gbc-hpvac.com), and to support its other ongoing projects, the GBC is pleased to announce that Silvia Hansel has joined the GBC team as Chief of Operations. Silvia will manage the day-to-day activities of the GBC, will be in charge of external communications and investor relations, and will oversee the GBC’s internal communication channels and documents. Her dynamic attitude, problem-solving skills and professional experience centered on organization, administration and customer relations nicely complement the pharmaceutical, medical and financial abilities of the other members of the GBC team. Prior to her arrival at the GBC, Silvia was board president and CEO of Kaleyde Pharmaceuticals, and an independent consultant for numerous years; her experience includes several activities in cultural and charitable organizations.